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Although dendritic cells (DCs) represent a small cell population in the body, they have been
recognized as professional antigen presenting cells and key players of both innate and
acquired immunity. The recent expansion of basic knowledge concerning differentiation
and function of various DC subsets will greatly help to understand the nature of protective
immunity required in designing acquired immunodeﬁciency syndrome (AIDS) vaccines.
However, human immunodeﬁciency virus (HIV) not only targets CD4+ T cells but also
myeloid cells, including macrophages and DC. When HIV infects DC, its replication is
highly restricted in DC. Nevertheless, even a low level of HIV production is sufﬁcient to
enhance HIV replication in activated CD4+ T cells, through antigen presentation activity by
HIV-infected DC. Considering how antiviral immunity is initiated and memory response is
maintained, such efﬁcient DC–T cell transmission of HIV should play an important role in the
disturbed immune responses associated with HIV infection. Recently, accessory proteins
encoded by HIV have been shown to interact with various proteins in DC, and thereby
affect DC–T cell transmission. In this review, we summarize the current understanding
about DC biology, antiviral immune responses and DC restriction factors, all of which will
be important issues for the development of an effective AIDS vaccine in the future.
Keywords: DC–T transmission, HIV, DC subsets, accessory proteins
INTRODUCTION
Since the discovery of dendritic cells (DCs) in the 1970s (Stein-
man, 2007), DC have long been recognized as: (1) professional
antigen presenting cells expressing high levels of major histo-
compatibility complex (MHC) class II and other costimulatory
molecules, (2) localizing to various tissues/organs, and (3) migrat-
ing to lymphoid tissues after antigen acquisition, to either initiate
immune responses or induce tolerance by interaction with T cells
(see review by Banchereau and Steinman, 1998).
In the 1990s, we (Tsunetsugu-Yokota et al., 1995) and sev-
eral others demonstrated that DC are easily susceptible to human
immunodeﬁciency virus type 1 (HIV-1) infection and can there-
fore also efﬁciently transmit virus to antigen-speciﬁcCD4+ T cells,
in spite of low levels of virus production. These earlier studies lead
to further research into the role of DC in the pathogenesis of
HIV infection, because DC–T cell interaction is considered to bet-
ter reﬂect the physiological mode of cell-to-cell HIV-1 infection
in vivo as compared to T-to-T or T-to-adherent cell interactions,
which involve env-mediated membrane fusion (Sattentau, 2008).
As our laboratory previously demonstrated, the close contact site
between DC–T cells is consolidated by the presence of T cell
receptor binding to MHC–antigen complex, followed by the inter-
action and mutual signaling of various costimulatory molecules
(Tsunetsugu-Yokota et al., 1997).
A substantial number of reviews, focusing on HIV-1 trans-
mission from DC to T cells (Rinaldo and Piazza, 2004; Wu and
KewalRamani, 2006; Piguet and Steinman, 2007) have illustrated
distinct features of cell-to-cell transmission. However, although
the majority of studies focus on the close contact as a virological
synapse (VS: a neuronal synapse like cell–cell contact structure
for spreading virus infection), most of them do not consider the
importance of antigen-dependent DC–T cell interaction, which is
well-recognized as an Immunological synapse (IS: a synapse like
cell–cell contact structure for activating immune response).
In this review, we will summarize the current understanding
of various human DC subsets based on several outstanding recent
ﬁndings inDCbiology andof antiviral immune responses initiated
by DCs, and discuss about newly identiﬁed DC restriction factors
counteracting HIV-1 accessory proteins (e.g., Vif, Vpu, and Nef),
whichmay have an impact on (1) the susceptibility of DC toHIV-1
infection and (2) the transmissibility of HIV from DC to T cells
via VS or IS.
BIOLOGY OF DENDRITIC CELLS
DC originate from common myeloid precursor cells in the bone
marrow, but are quite heterogeneous in terms of their localization,
surface phenotype, and function. The major DC subsets are classi-
cal or conventional DC (cDC) and plasmacytoid DC (pDC). The
development pathway and the lineage relationship of these DCs
have been subjects of extensive investigation (see review by Stein-
man and Idoyaga, 2010). By analyzing bone marrow precursors
in vivo, a current view of DC development and homeostasis has
been established. In the bone marrow, monocytes and DC pre-
cursors (MDP) ﬁrst develop into a common DC precursor (CDP)
before continuing development into either a monocyte, or a cDC
precursor (PreDC) and pDC, respectively (Fogg et al., 2006; Liu
et al., 2009). PreDC, pDC, and monocytes subsequently migrate
through blood to the spleen and lymph nodes, whereby preDC
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differentiate into cDC in the presence of Flt3L, and monocytes dif-
ferentiate into either macrophages or DC, presumably depending
on the inﬂammatory stimuli present (Cheong et al., 2010).
With regards to lineage, there is considerable difference between
mouse and human DC subsets, as deﬁned by surface markers.
Five major DC subsets are known in mice: CD8+DC, CD4+DC,
and pDC in lymphoid tissues, and CD103+ and CD11b+DC in
non-lymphoid tissues (Steinman and Idoyaga, 2010). Alternately,
the source of DC in humans is more limited, originating from
either skin or blood. In human skin, three DC subsets have been
identiﬁed: epidermal CD207+ Langerhans cells (LCs), CD14+
dermal DC, and CD14−CD207−CD1a+ DC. Amongst them, LC
are the most potent inducer of Th2 cytokines and able to cross
prime CD8+ effector cells (Klechevsky et al., 2008). With respect
to the origin of LC localized in the skin epidermis, Sere et al.
(2012) have recently reported that LC are replenished in two
waves, one by monocyte-derived, short lived LC upon inﬂam-
mation, and the other by non-blood monocyte origin with long
life expectancy (Sere et al., 2012). In other tissues and blood, two
subsets of human cDC are known, which express either CD1c
(BDCA-1) or CD141 (BDCA-3). The other group, pDC, expresses
human-speciﬁc pDC markers, BDCA-2 and BDCA-4, in addition
to CD123 [interleukin-3 receptor (IL-3R)], and produces a large
amount of type I interferon (IFN; Steinman and Idoyaga, 2010).
A unique and important function of DC is their cross-
presentation ability by phagocytosing dead cells, tumor cells,
or infected cells, which results in the activation of MHC class
I-restricted effector CD8+ T cells (Bevan, 2006). A particular
subset of DC is known to efﬁciently cross-present antigens. In
mice, splenic CD8α DC are the most potent DC subset for cross-
presentation, and the human counterpart of mouse CD8α has
been recently identiﬁed (Bachemet al.,2010; Jongbloed et al.,2010;
Poulin et al., 2010).
The minor DC population in human blood, CD141+ DC,
shares several phenotypic and functional properties with mouse
CD8α DC, such as: (1) the expression of DC natural killer (NK)
lectin group receptor-1 (DNGR-1)orCLEC9A,a sensor of necrotic
cells (Sancho et al., 2009), and (2) the selective expression of
the chemokine receptor XCR1 (Bachem et al., 2010), transcrip-
tional factor ATF (activating transcription factor)-like-3, and IFN
regulatory factor 8 (IRF-8). CD141+ DC also express a high
level of Toll-like receptor 3 (TLR3) and upon TLR3 stimulation,
produce IL-12 and IFN-β. More recently, by using comparative
genomics to align human and mouse cell types, Haniffa et al.
(2012) demonstrated that cutaneous CD141hi CLEC9AhiXCR1+
DC, which are closely related to blood CD141hi CLEC9AhiXCR1+
DC, are much more potent at cross-presentation than LC. Taken
together, in humans, CD141+DC, CD1c+DC, and pDC local-
ize within lymphoid tissues, while the former two types of DC
and CD14+ DC are present in non-lymphoid tissues. In addition,
human tissue CD141+ DC are functional homologues of mouse
CD103+(α chain of the αEβ7 integrin) non-lymphoid DC, with
high cross-presentation activity (Haniffa et al., 2012).
However, the relationship between DC and mono-
cytes/macrophages can sometimes be confusing when based
only on cell surface markers and functional properties.
Two types of human monocytes are present in the blood:
“patrolling” CD14dimCD16+ and inﬂammatory CD14+ CD16−
or CD14+CD16+monocytes, which resemble mouse Gr−
(Ly6Clow) and Gr+ (Ly6Chigh) cells, respectively (Auffray et al.,
2009; Cros et al., 2010). When tissue inﬂammation occurs,
CD14+inﬂammatory monocytes migrate to the site of inﬂam-
mation, and may differentiate into CD11b+CD14+ monocyte-
derived DCs (MDDCs) as demonstrated in mice (Cheong et al.,
2010).
Currently, four major DC subsets comprise and make up the
category of DC: cDC, pDC, LCs, and MDDCs (Satpathy et al.,
2012). A recent large scale collaborative study focusing on the
transcriptional network of DC and monocyte/macrophage sub-
sets, highlighted on some lineage-speciﬁc key transcriptional
factors and the mutual relationship between DC and mono-
cytes/macrophages (Miller et al., 2012), though the deﬁnition of
DC by molecular signatures has raised further discussion (Hume
et al., 2013).
Incorporating recent ﬁndings, the development and lin-
eage relationship of human myeloid precursors is illustrated in
Figure 1.
OVERVIEW OF ANTIVIRAL IMMUNE RESPONSES IN ACUTE
AND CHRONIC HIV INFECTION
The natural infection of HIV-1 mostly occurs through vaginal
or rectal routes. Because these submucosal spaces are rich in DC,
they have been argued to be the primary targets of HIV-1 infection
(see reviews byWu and KewalRamani, 2006; Piguet and Steinman,
2007). However, detection of HIV-1-producingDC in these tissues
is rare, which is in contrast to the rapid and massive HIV/simian
immunodeﬁciency virus (SIV) infection detected inCD4+CCR5+
memory T cells (Brenchley et al., 2004; Mehandru et al., 2004; Li
et al., 2005; Mattapallil et al., 2005). Nonetheless, the scenario that
mucosally residing, non-producing HIV-infected DC or phagocy-
tosed HIV-1-infected DC migrate to regional lymph nodes, and
subsequently spread HIV-1 infection there to contacting T cells,
in association with nominal antigen presentation, well reﬂects
whatmaybeoccurring in lymphoidorgans (WuandKewalRamani,
2006; Piguet and Steinman, 2007).
In a chronic stage of HIV-1 infection, amajor reservoir of latent
HIV-1 infection is considered to be the circulating resting mem-
ory T cells, carrying integrated HIV-1 DNA (review by Pierson
et al., 2000). When resting memory cells enter a lymphoid organ,
they interact with resident DC,which may induce T cell activation
and concomitant transmission of reactivated HIV-1 to DC. There
is a possibility that newly HIV-infected DC can transmit virus to
intact naïve or memory T cells. Although these HIV-1-infected
T cells and DC can be eliminated by a cytotoxic T cell (CTL)
response, a continuous cycle of such aforementioned events may
cause intermittent surges of plasma viral load under chronic infec-
tion. Henceforth, lymphoid organs are considered to bemajor sites
of HIV-1 production.
During the induction of primary immune responses in lym-
phoid organs, an inﬂammatory response can occur, as an innate
immune mechanism at the invasion site, attracting a variety of
immune cells, including T cells and monocytes. As previously
described, so-called inﬂammatory monocytes are recruited into
peripheral tissues subsequently, differentiating into inﬂammatory
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FIGURE 1 | Development of myeloid cells and lineage relationship
between DC subsets. Hematopoietic stem cells in the bone marrow
differentiate into monocyte/macrophage and DC precursor (MDP),
which commits to a distinct lineage cell, either becoming a monocyte
or common DC precursor (CDP). CDP differentiates to preDC or pDC,
and migrates to the peripheral tissues through blood. In the lymphoid
or non-lymphoid tissues, preDC can become either of two types of
cDC: CD1c+ DC and CD141+/XCR1+/CLEC9A+ DC, the latter of
which has high cross-presenting activity. In the blood, CD14+ or CD16+
monocytes are also circulating. Blood monocytes are source of macrophages
(Mφ), LC, and microglias. The other LC precursor in the bone marrow, was
also shown to migrate to the skin. Upon tissue inﬂammation, CD14+
monocytes migrate to the inﬂamed tissue and differentiate into either
migratory MDDC or inﬂammatory Mφ. It is known that the cells committed
to become DC express Flt3, whereas those that commit to monocytes/
macrophages express M-CSF receptor. Therefore, Flt3L and M-CSF are key
molecules for differentiation and proliferation of DC and monocytes/
macrophages, respectively.
MDDC which can regulate immune responses locally (Cheong
et al., 2010).
It is well-known that effector CD8+ T cells play an essential
role regarding protection against HIV/SIV infection (Appay et al.,
2008). Once infection primes in lymphoid organs, memory CD8+
T cells can act as effector cells by circulating in the blood, in order
to migrate to infected tissues upon re-exposure, and quickly elimi-
nate infected cells. The importance of long-term resident memory
CD8+T (TRM) cells has been highlighted with respect to efﬁcacy
of the local memory response (Gebhardt and Mackay, 2012). By
utilizing an elegant mouse model of herpes simplex virus (HSV)
infection, memory CD8+ T cells were shown to be initiated in
extra-lymphoid tissues, independent of migratory memory CD8+
T cells (Wakim et al., 2008). In this model, HSV-infected dor-
sal root ganglia (DRG) was surgically transplanted to naïve mice,
because DRG is known to be latently infected with HSV, after
acute virus resolution, and to be reactivated by surgical extraction.
Stimulation of these CD8+TRM cells was dependent on recruited
DC in the DRG, and CD4+T cell help was required. These CD8+
TRM cells represent a self-renewing and highly protective popula-
tion of memory T cells distinct from circulating memory CD8+ T
cells, and express CD103 which is known to be widely expressed
in non-lymphoid tissues (Gebhardt et al., 2009). Interestingly, a
study using intravital two-photon microscopy revealed that while
memory CD4+ T cells are trafﬁcked rapidly, CD8+ TRM cells are
removing slowly in the original skin site during HSV infection
(Gebhardt et al., 2011).
The functional properties of CD8+ TRM cells have just begun
to be elucidated in inﬂuenza virus infection. The innate antiviral
function of IFN-induced transmembrane protein 3 (IFTM3) was
ﬁrst discovered by using RNA interference screening for factors
modifying inﬂuenza virus infection (Brass et al., 2009). The IFITM
family is: (1) made up of IFN-stimulated genes (ISGs) with diverse
biological functions, (2) comprises of multiply closed members of
four genes in both humans andmice, and (3) restricts various virus
infections at a site of viral fusion (Diamond and Farzan, 2012).
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Recently, IFITM3 was reported to be expressed in lung CD8+ TRM
cells after inﬂuenza virus infection, endowing greater resistance
to the secondary inﬂuenza virus infection (Wakim et al., 2013).
Sustained expression of IFITM3 is intrinsically regulated in CD8+
TRM, but not CD4+ memory T cells, and enhances the survival
of CD8+ TRM cells only at sites of viral infection. Although the
involvement of recruited DCs on the activation of CD8+ TRM cells
is demonstrated (Wakim et al., 2008), the mechanisms in which
memory and effector CD8+ T cells develop and localize to target
peripheral tissue such as intestinal mucosa and the involvement of
intestinal DCs need to be addressed in future for the development
of effective anti-HIV vaccines.
The overview of this section is illustrated as Figure 2.
DISTINCT SUSCEPTIBILITY OF DCs TO HIV: CIS- AND
TRANS-INFECTION MODES
WhenMDDCare activated by various stimuli, such as lipopolysac-
charide (LPS), TLR ligands, cytokines like type I IFN, DC express
higher levels of MHC class II and other costimulatory molecules,
thereby engaging in antigen presentation rather than antigen
uptake. This maturation status and difference in lineage can pro-
foundly affect the susceptibility of DC to HIV-1 infection (see
review by Wu and KewalRamani, 2006).
Dendritic cell express various C-type lectin receptors (CLRs)
which bind to HIV-1, such as DC-SIGN (dendritic cell-speciﬁc
intercellular adhesion molecule-3-grabbing non-integrin), Lan-
gerin, and dectin (Turville et al., 2002), and recently discovered
CLEC9A (Caminschi et al., 2008; Huysamen et al., 2008; Sancho
et al., 2009). Each lectin receptor appears to have a unique and
distinct function. HIV-1 transfer in trans, through the capture of
virus by a CLR, such as DC-SIGN, occurs early in in vitro exper-
iments (Cavrois et al., 2007; Dong et al., 2007; Izquierdo-Useros
et al., 2007), and is designated trans-infection. However, DC lectin
receptors are important molecules involved in the presentation
of foreign antigens. In fact, the most of the HIV-1 virions cap-
tured by DCs were known to be rapidly degraded (Turville et al.,
2004; Nobile et al., 2005). Moreover, the interaction of leukocyte-
speciﬁc protein 1 (LSP-1), a protein directing internalized virus
to the proteasome, with the cytoplasmic region of DC-SIGN may
further facilitate the degradation of HIV-1 (Smith et al., 2007).
FIGURE 2 | HIV infection andT cell differentiation during primary and
memory antiviral immune responses. A general view of antiviral immune
responses focusing on HIV-1 infection is illustrated. Once HIV invades the
vaginal mucosa, infection mostly occurs in activated CD4+CCR5+ T cells (1).
Resident DCs in the submucosa engulf virions or HIV-infected cells (2), and
then migrate to the draining lymph nodes (3), where an antiviral immune
response is initiated (4). In a primary immune response, antigen-speciﬁc
T cells are differentiate into effector cells. During the effector phase, memory
T cells are also produced, the mechanism of which is not fully understood.
Once activated, CD4+ T cells are infected with HIV (5), however, most
effector cells will die of apoptosis (6), or killed by effector CD8+ T cells (7).
When virus-infected cells are eliminated in the infection site, the immune
response enters into the contraction phase. After some time, memory T cells
revert to quiescent or resting state (8) and circulate back to peripheral tissues
for checking for next infection. Latent infection of HIV is known to occur in
such quiescent memory CD4+ T cells. When these latently HIV-infected
memory CD4+ T cells interact with uninfected DCs andT cells, for secondary
antigen exposure, HIV-1 may spread to CD4+ T cells in the lymphoid organ
through DC–T cell interaction (9). In the case of circulating memory CD8+
T cells (mCD8), they may quickly enter into tissues to eliminate the secondary
infection (10). However, recent evidence indicate that tissue resident CD8+
T cells (TRM) (11) primed in situ play a more important role than circulating
mCD8 in protective immunity, which may be a distinct feature from memory
CD4+ T cells.
Frontiers in Microbiology | Virology July 2013 | Volume 4 | Article 178 | 4
“fmicb-04-00178” — 2013/7/5 — 20:51 — page 5 — #5
Tsunetsugu-Yokota and Muhsen DC development and HIV transmission
On the other hand, HIV-1 replication in DCs, but not DC-
SIGN, is required for long-term transfer of HIV from DCs to
CD4+ T cells (Lore et al., 2005; Nobile et al., 2005; Burleigh et al.,
2006; Wang et al., 2007). Although DCs can support only min-
imal replication of HIV-1 (DC restriction, see Restrictions in
DCs), it is considered that the antigen-dependent close DC–T
cell contact, forming IS, would support the efﬁcient virus trans-
mission followed by massive virus replication in CD4+ T cells
(Tsunetsugu-Yokota et al., 1995; Lore et al., 2005). We assume that
such cis-infection is more likely to occur in vivo, as opposed to
trans-infection.
Thus, the trans-infection in vitro needs to be discriminated
from HIV-1 transmission in cis or cis-transmission through
genuine infection via DC as shown in Figure 3.
THE ROLE OF TETHERIN IN HIV TRANSMISSION:
IMMUNOLOGICAL SYNAPSE VERSUS VIROLOGICAL
SYNAPSE
Various intrinsic antiviral mechanisms or factors have evolved in
eukaryotes to ﬁght against virus invasion (see review by Yan and
Chen, 2012). To countermeasure these intrinsic cellular factors
(restriction factors), HIV-1 evolved to encode several accessory
proteins, such as Vpu, Vif, Vpr, and Vpx. BST-2/CD317/tetherin
was recently identiﬁed as one such cellular factor, antagonized
by HIV-1 Vpu (Neil et al., 2008; Van Damme et al., 2008). Nor-
mally, BST-2/tetherin inhibits virion release by anchoring virus at
the cell membrane, but Vpu can directly bind to BST-2/tetherin,
internalizing and degrading it, probably in the endolysosomal
compartment (Arias et al., 2012).
It has been known for some time that vpu mutant virus can be
efﬁciently spread by T cell to T cell transfer (Gummuluru et al.,
2000) in a rapid turnover HIV-1 replication culture. As such, this
observation raises the important question of whether Vpu affects
cell-to-cell spread of HIV-1 by inhibiting the membrane tether-
ing function of BST-2/tetherin? This issue was addressed under
the setting of a VS, using HIV-infected cells directly contacting
with an uninfected target cell system. Jolly et al. (2010) found that
Vpu-defective HIV-1 disseminates more efﬁciently through cell-
to-cell contact, despite the premise that BST-2/tetherin inhibits
cell-free virion release, which corroborates with a previous report
by Gummuluru et al. (2000), in which the authors speculated that
BST-2/tetherin either mediates the accumulation of virions or reg-
ulation of VS integrity. On the other hand, Casartelli et al. (2010)
studied virus transfer to T cells (targets) from HeLa or 293T cells,
expressing a high level of BST-2/tetherin either naturally or by
transfection (donors). They observed that BST-2/tetherin does
not prevent VS formation, but assists the accumulation of Gag
at the contact zone in the absence of Vpu (Casartelli et al., 2010).
Important to note, however, is since the authors used mostly vesic-
ular stomatitis virus (VSV)-pseudotyped HIV-1 for the infection
of donors, their system is a transient infection event without new
infectious virus production and reﬂect a cell-to-cell trans-infection
as discussed in a previous section. Regardless, in both studies
(Casartelli et al., 2010; Jolly et al., 2010), the accumulation of HIV-
1 virions, in the presence of a high level of tetherin expression was
observed.
Alternately, Kuhl et al. (2011) reported that a Vpu-mediated
effect in viral spread among CD4+ T cells is independent of
FIGURE 3 | Distinct HIV transmission mode by DCs: Cis- and
Trans-infection.There are two modes of transmission of HIV from DC to
T cells. (A)Trans-infection: DCs express various receptors to bind foreign
antigens, which is important to efﬁciently endocytose and process for antigen
presentation. Such machinery is highlighted for HIV transfer in trans in in vitro
experiments. However, because endocytosed antigens are quickly degraded
within 24 h (Turville et al., 2004), infectious HIV particles may not retain their
infectivity for a long time. Thus, the physiological relevancy of trans- infection
in vivo remains unclear. (B) Cis-infection: On the other hand, because DC
express CD4 and chemokine receptors essential for HIV infection, DC are
naturally susceptible to HIV infection. Although HIV replication is limited in
DC, their strong antigen-presenting activity allows HIV to replicate more in
antigen-speciﬁc CD4+ T cells tightly interacting with DC. This DC–T cell
interaction is a genuine immunological synapse (IS). The precise molecular
mechanism of HIV transmission from DC toT cells has yet to be clariﬁed,
but the cis-infection mode, is what most likely occurs in vivo.
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the extent of Vpu-mediated BST-2/tetherin cell surface down-
modulation. They postulated the presence of an additional Vpu-
independent mechanism for BST-2/tetherin cell surface down-
modulation following HIV-1 infection in T cell lines, which is
consistent with a report by Miyagi et al. (2009).
Vpu interacts with BST-2/tetherin to promote virion release,
whereas BST-2/tetherin normally causes accumulation of virus
particle on the membrane surface. However, the efﬁciency of cell-
to-cell HIV-1 transfer or transmission appears largely dependent
on experimental conditions. As previously described, DC–T cell
contact is not equal to theVS formof contact. Therefore,we should
perhaps consider the physiological function of BST-2/tetherin,
under the setting of an antigen-mediated IS instead.
In this context, Coleman et al. (2011) reported that immature
MDDC does not express BST-2/tetherin, however, after HIV-1
infection, BST-2/tetherin expression was upregulated by HIV-1
Nef. Therefore, HIV-1 transmission from DC to T cells does not
appear to be restricted by BST-2/tetherin (Coleman et al., 2011).
However, because their target is theHUT/CCR5T cell line and cul-
ture conditions favor trans infection (immediate co-culture after
HIV-1 infection), the question of whether cell surface expression
of BST-2/tetherin assists or inhibits virus transmission to CD4+T
cells via IS needs to be clariﬁed.
RESTRICTIONS IN DCs
The poor replication of HIV in DC is partly explained by a block
during virus fusion with MDDC (Cavrois et al., 2006). The restric-
tion of HIV-1 infection in DC can also occur at a post-entry level.
Several cell factors known to interfere with HIV-1 infection and/or
replication step in DC are illustrated in Figure 4. APOBEC3 was
originally discovered as a potent intrinsic antiviral factor interact-
ing with HIV-1 Vif (Sheehy et al., 2002). APOBEC3G (A3G) is a
member of the cytidine deaminase family, which edits C to U in a
single stranded HIV DNA, causing G-to-A hyper mutation of the
HIV-1 genome. HIV-1 Vif counteracts this deaminase function
by inhibiting A3G incorporation into virions and promoting A3G
degradation by ubiquitination (Sheehy et al., 2003).
Myeloid cells differentiate from monocytes to either
macrophages or immature MDDC, and susceptibility to HIV-1
infection amongst these cell types has been inversely correlated to
FIGURE 4 | DC restriction and type I IFN response. HIV-1 utilizes CD4
and chemokine receptors for entry. The restriction of cDC to HIV-1
infection occurs at the entry (fusion) and post-entry level. Of note,
in order to investigate the step at the post-entry level, VSV-pseudotyped
virus is frequently utilized, which enters cells by endocytosis. After entry,
APOBEC3G and arsenic sensitive factor inhibit reverse transcription.
However, Vpx can counteract this restriction in DC by either degrading
(1) SAMHD1-nucleotide pool-reverse transcription pathway or
(2) nuclear transport. In addition, because the proteasome inhibitor MG132
works in a similar fashion to Vpx, it is possible that Vpx interferes with the
proteasomal degradation step of endocytosed virions by degrading DC
factors other than SAMHD1.Whatever the case, Vpx causes the
accumulation of numerous virus products in the cytosol (red arrows).
Importantly, the accumulation of viral DNA and RNA may trigger the innate
immune signaling, resulting in type I IFN production, followed by the
maturation of DC.
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A3G expression, with highest A3G expression and lowest HIV-1
susceptibility in monocytes (Peng et al., 2007). In MDDC, A3G
and APOBEC3F were shown to restrict HIV-1 infection at a post-
entry step by Pion et al. (2006) and can be mainly ascribed to
the deaminase-independent A3G function that inhibits reverse
transcription (Bishop et al., 2008). However, Pion et al. (2006)
also observed that arsenic trioxide enhanced the reverse tran-
scription of HIV-1 in MDDC and CD1c+ blood cDC in an
A3G-independent manner (Pion et al., 2007). Although the mech-
anism of arsenic in DC is currently unknown, these results suggest
that cellular factors, other than APOBEC3, are deﬁnitely playing
important roles in the restriction of HIV-1 replication, most likely
at a reverse transcription step, in DC.
Coincidentally, a novel DC restriction factor was discovered
from a study on Vpx. SIV virus like particles (VLPs) containing
Vpx are known to enhance the expression of VSV-G-pseudotyped
lentivirus in DC (Santini et al., 2000), and this ﬁnding lead to
the identiﬁcation of SAMHD1, a myeloid cell restriction factor
(Caminschi et al., 2008; Hrecka et al., 2011). SAMHD1 is a potent
triphosphohydrolase that converts deoxynucleoside triphosphates
(dNTPs) to deoxynucleoside and triphosphate (Goldstone et al.,
2011). Therefore, the current working hypothesis for the rela-
tionship between Vpx and SAMHD1 is that virus containing Vpx
can replicate well in macrophages by degrading SAMHD1, which
would otherwise reduce the dNTP pool and inhibit reverse tran-
scription (Lahouassa et al., 2012). In SIVSM or HIV-2 infection,
Vpx was shown to be essential for viral replication and critical for
reverse transcription of the viral RNA genome in macrophages
(Fujita et al., 2008). However, a lack of Vpx in HIV-1 has negli-
gible consequence with HIV-1, which can substantially replicate
in macrophages. Therefore, Fujita et al. (2012) hypothesized that
because of the lower activity of reverse transcriptase in HIV-2
versus HIV-1, HIV-2 had evolved to carry Vpx for compensation
(Fujita et al., 2012).
However, it should bementioned that immatureMDDCdonot
support HIV-1 replication, in a similar manner, as macrophages
do in R5-type HIV-1 infection (Tsunetsugu-Yokota et al., 1995)
and that the susceptibility of HIV-2 containing native Vpx is even
lower in MDDC and blood cDC (Smith et al., 2007). Furthermore,
although remarkable Vpx-induced enhancement is observed in
the case of VSV-pseudotyped lentivirus infection, it is not so obvi-
ous when native HIV was co-infected with SIV-VLP (Manel et al.,
2010). Because it is known that the way virus enters via HIV enve-
lope and/or VSV glycoprotein can lead to distinct outcomes in
CD4+ T cells (Yu et al., 2009), the HIV envelope and its signaling
in DC may contribute to different effects of Vpx.
There is no convincing explanation as towhy theDCrestriction,
common tonaturalHIV-1 andHIV-2 infections,wouldnecessarily
bemediated byVpx causing SAMHD1degradation per se. Consid-
ering that the proteasome inhibitor, MG132, exerts similar effects
with Vpx (Groot et al., 2006), we speculate that Vpx delivered
into endosomes may inhibit endosomal degradation of endocy-
tosed VSV-based lentivirus vector, which results in the release of
numerous viral particles into the cytosol followed by production
of a high copy number of RT products, thereby enhancing all
subsequent steps of HIV-1 infection (integration, RNA synthesis,
nuclear export, etc.). This scenario still needs to be proven and
validated. Determination of whetherVpx induces the degradation
of DC factors, other than SAMHD1, will prove to be an interesting
future endeavor.
Vpx AND TYPE I IFN
Another interesting feature of Vpx is that SIV-VLP containing
Vpx induces a high level of Type I IFN in DC (Manel et al., 2010).
Genetic diseases lacking SAMHD1 and TREX, a recently identiﬁed
3′-exonuclease which can suppress excess DNA accumulation in
the cell (Yan et al., 2010), are known to develop similar autoim-
mune diseases due to a high level of type I IFN production (Lim
and Emerman, 2011), indicating that these two distinct cellular
proteins are important to regulate type I IFN responses. Thus,
it is safe to assume that SAMHD1 degradation by Vpx can con-
tribute to the induction of a high level of type I IFN production in
DC.However, becauseVpx enhances intracellular virus replication
events as described in the previous section, excess accumulation
of proviral DNA, as well as viral RNA, will occur, which might
act as triggers for innate immune signaling in DC as depicted in
Figure 4.
In contrast to other RNA viruses such as measles and inﬂuenza
infection (Zilliox et al., 2006), HIV-1 infection, and other retro-
viruses also, do not induce type I IFN responses in DC (Luban,
2012). As regards to the mechanism, IRF-3, a pathogen-sensing
pathway component, was shown to be depleted in HIV-infected T
cells (Doehle et al., 2009) but not in DC, whereas Vpr-dependent
inhibition of IRF-3 nuclear translocation was reported to occur
in DC (Harman et al., 2011). The stimulation of DNA- and/or
RNA-sensing pathway by Vpx may overcome this Vpr effect in
DCs.
Finally, it is well-known that type I IFN is one of a multitude of
cytokines which can induce the maturation of DC (Santini et al.,
2000), and the maturation of MDDC has been shown to block
HIV-1 infection at a post-entry level (Dong et al., 2007). However,
in pDC, type I IFN production is induced by HIV-1 infection, as
with other virus infections, resulting in inhibition on HIV-1 repli-
cation (Groot et al., 2006). Therefore, the lack of innate immune
responses in cDC will be compensated in vivo in the early phase
of HIV infection. Surprisingly, Schlafen 11 (SLFN11), a molecule
induced by type I IFN, was shown to inhibit the translation of
HIV-1 based on its virus-speciﬁc codon usage (Li et al., 2012).
This ﬁnding indicates that there are still many undiscovered fac-
tors related to type I IFN signaling inDCwhichmaybe exploited to
ﬁght against retrovirus infections. Alternately, from the HIV side
of things, by counteracting these restriction factors, HIV is able
to establish a low level infection in DC. However, once type I IFN
is induced in DC, it will help to generate more potent antigen-
presenting DC, as demonstrated by Manel et al. (2010). Vaccine
strategies utilizingVpx for the enhancement of antigen presenting
cell (APC) function in DC have already began and look promising
(Durand et al., 2013).
CONCLUSION
We now recognize that the majority of recently identiﬁed cellular
factors interacting with HIV accessory proteins are related to the
type I IFN or innate immune response. The remarkable antiviral
activity of type I IFN has been well-known for a long time, but we
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are just beginning to understand its precise mechanism, which is
not necessarily common to all cell types, especially in DC. It is has
been postulated that HIV has evolved to escape from potent anti-
gen presenting activity of DC, and took advantage of subverting
within DC with a minimum level of replication, for easy trans-
mission of virus to T cells, during the T cell activation process. As
described in this review, our knowledge concerning the biology
of various subsets of DC has advanced enormously. However, we
need to further apply this basic knowledge and understanding to
manipulate DC by placing them in crucial sites (tissues), within
proper time frames, for the development ofa protective acquired
immunodeﬁciency syndrome (AIDS) vaccine.
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